Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2015 Sep 1;25(17):3661-4. doi: 10.1016/j.bmcl.2015.06.046. Epub 2015 Jun 18.

Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.

Author information

1
Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, United States. Electronic address: jackzhang49@yahoo.com.
2
Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, United States.

Abstract

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.

KEYWORDS:

CCR9; Crohn’s disease; IBD; Sulfonamide; Ulcerative colitis

PMID:
26117562
DOI:
10.1016/j.bmcl.2015.06.046
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center